MedPath

Verastem

Verastem logo
🇺🇸United States
Ownership
Public
Established
2010-01-01
Employees
73
Market Cap
-
Website
http://www.verastem.com
Introduction

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients

Phase 2
Recruiting
Conditions
Low Grade Serous Ovarian Cancer
Ovarian Cancer
Interventions
First Posted Date
2024-11-12
Last Posted Date
2025-02-17
Lead Sponsor
Verastem, Inc.
Target Recruit Count
15
Registration Number
NCT06682572
Locations
🇯🇵

Aichi Cancer Center Hospital, Nagoya, Aichi, Japan

🇯🇵

Kurume University Hospital, Kurume, Fukuoka, Japan

🇯🇵

Mie University Hospital, Tsu, Mie, Japan

and more 2 locations

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

First Posted Date
2023-10-10
Last Posted Date
2025-05-21
Lead Sponsor
Verastem, Inc.
Target Recruit Count
270
Registration Number
NCT06072781
Locations
🇺🇸

HonorHealth, Phoenix, Arizona, United States

🇺🇸

University of Arkansas, Little Rock, Arkansas, United States

🇺🇸

UCLA Health, Los Angeles, California, United States

and more 88 locations

Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

Phase 1
Recruiting
Conditions
Metastatic Cancer
Pancreas Cancer
Neoplasms Pancreatic
Malignant Neoplasm of Pancreas
KRAS Activating Mutation
Interventions
First Posted Date
2022-12-30
Last Posted Date
2025-05-18
Lead Sponsor
Verastem, Inc.
Target Recruit Count
40
Registration Number
NCT05669482
Locations
🇺🇸

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

🇺🇸

University of Chicago, Chicago, Illinois, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 9 locations

Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

Phase 1
Active, not recruiting
Conditions
Non Small Cell Lung Cancer
KRAS Activating Mutation
Advanced Cancer
Metastatic Cancer
Malignant Neoplastic Disease
Malignant Neoplasm of Lung
Interventions
First Posted Date
2022-05-17
Last Posted Date
2025-05-18
Lead Sponsor
Verastem, Inc.
Target Recruit Count
85
Registration Number
NCT05375994
Locations
🇺🇸

UCSF Thoracic Oncology, San Francisco, California, United States

🇺🇸

University of Colorado Hospital Anschutz Cancer Pavllion, Aurora, Colorado, United States

🇺🇸

Mayo Clinic Cancer Center, Rochester, Minnesota, United States

and more 4 locations

Food Effect of VS-6766 in Healthy Adult Subjects

Phase 1
Completed
Conditions
Food Effect
Interventions
First Posted Date
2022-01-11
Last Posted Date
2022-05-10
Lead Sponsor
Verastem, Inc.
Target Recruit Count
18
Registration Number
NCT05187169
Locations
🇺🇸

Celerion, Tempe, Arizona, United States

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

Phase 1
Recruiting
Conditions
KRAS Activating Mutation
Non Small Cell Lung Cancer
Interventions
First Posted Date
2021-10-12
Last Posted Date
2025-02-04
Lead Sponsor
Verastem, Inc.
Target Recruit Count
153
Registration Number
NCT05074810
Locations
🇫🇷

Hôpital Foch, Suresnes, France

🇺🇸

Rocky Mountain Cancer Center, LLP, Boulder, Colorado, United States

🇺🇸

Georgetown University Medical Center, Washington, District of Columbia, United States

and more 29 locations

A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS Mutation

Phase 2
Active, not recruiting
Conditions
Low Grade Ovarian Serous Adenocarcinoma
Ovarian Cancer
Interventions
First Posted Date
2020-11-12
Last Posted Date
2025-01-29
Lead Sponsor
Verastem, Inc.
Target Recruit Count
225
Registration Number
NCT04625270
Locations
🇺🇸

The Ohio State University Wexner Medical Center, Columbus, Ohio, United States

🇺🇸

Sansum Clinic, Santa Barbara, California, United States

🇺🇸

University of Chicago, Chicago, Illinois, United States

and more 41 locations

A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Phase 2
Completed
Conditions
KRAS Activating Mutation
Non Small Cell Lung Cancer
Interventions
First Posted Date
2020-11-06
Last Posted Date
2024-01-12
Lead Sponsor
Verastem, Inc.
Target Recruit Count
90
Registration Number
NCT04620330
Locations
🇺🇸

Hematology/Oncology Clinic, LLP, Baton Rouge, Louisiana, United States

🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

🇺🇸

Illinois Cancer Specialists, Niles, Illinois, United States

and more 40 locations

Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer

Phase 1
Terminated
Conditions
Epithelial Ovarian Cancer
Interventions
Drug: Part A - VS-6063
Drug: Part A - Avelumab
First Posted Date
2016-10-24
Last Posted Date
2019-04-30
Lead Sponsor
Verastem, Inc.
Target Recruit Count
98
Registration Number
NCT02943317
Locations
🇺🇸

Florida Cancer Specialists & Research Institute (FCS), Sarasota, Florida, United States

🇺🇸

Dana Farber Cancer Instiyute, Boston, Massachusetts, United States

🇺🇸

Stephenson Cancer Center (University of Oklahoma), Oklahoma City, Oklahoma, United States

and more 2 locations

A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
First Posted Date
2016-09-26
Last Posted Date
2017-01-30
Lead Sponsor
Verastem, Inc.
Target Recruit Count
5
Registration Number
NCT02913716
© Copyright 2025. All Rights Reserved by MedPath